| Code | CSB-RA012887MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to oloctinebart, targeting LGALS3 (Galectin-3), a beta-galactoside-binding lectin involved in critical cellular processes including cell adhesion, proliferation, differentiation, and apoptosis. LGALS3 plays a significant role in immune regulation, inflammation, and fibrosis through its interactions with glycoproteins and glycolipids on cell surfaces and in the extracellular matrix. Elevated LGALS3 expression has been implicated in various pathological conditions, including fibrotic diseases, heart failure, cancer progression, and metastasis, where it promotes tumor cell survival, angiogenesis, and immune evasion.
Oloctinebart represents a therapeutic antibody designed to inhibit LGALS3 activity, currently being investigated for its potential in treating fibrotic conditions and cancer. This biosimilar antibody provides researchers with a valuable tool for investigating LGALS3-mediated pathways, exploring disease mechanisms, and conducting preclinical studies related to fibrosis, cardiovascular disease, oncology, and immunology. It enables detailed examination of Galectin-3's multifaceted roles in disease pathogenesis and therapeutic intervention strategies.
There are currently no reviews for this product.